The effective shelf and ATM facility create immediate dilution overhang for a $37M market cap clinical-stage biotech. Monitor for any prospectus supplement or takedown announcement — the ATM can be used at any time without further disclosure. The stock may face downward pressure as the market prices in potential dilution.
Price Chart
Executive Summary
Tvardi Therapeutics' S-3 shelf registration (File No. 333-287675) became effective on May 13, 2026. The shelf allows the company to sell up to $200M in common stock, preferred stock, debt securities, and/or warrants, including up to $12.5M via an at-the-market (ATM) facility with JonesTrading. This creates immediate dilution overhang for the $37M market cap issuer, as the ATM alone represents ~34% of current market cap.
Key Facts
- Shelf registration effective May 13, 2026, covering up to $200M in securities.
- Includes an ATM facility for up to $12.5M of common stock via JonesTrading.
- Market cap is $37M — the ATM alone represents ~34% of current market cap.
- The company is a clinical-stage biotech (former Cara Therapeutics) with no approved products.
- Cross-filing context: S-3 filed May 1, 2026, now effective — immediate ability to sell shares.
Financial Impact
Up to $200M in securities can be sold; $12.5M ATM facility is ~34% of current $37M market cap, creating significant dilution risk.
Risk Factors
- Immediate dilution risk from ATM sales — up to 34% of current market cap.
- Clinical-stage company with no approved products — any equity issuance further pressures existing holders.
- Shelf allows multiple types of securities (debt, preferred, warrants) — terms unknown.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001601 |
| Document: 9999999995-26-001601-index.html | 9999999995-26-001601 |
| Document: 9999999995-26-001601.txt | 9999999995-26-001601 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 9w ago | Institutional Cluster | $1.86 $1.61 | ▲ +13.44% | ▲ +12.91% | $0.8650 (+53.49%) |
Aug 14, 2026 10w ago | 8-K | $1.90 $1.83 | ▼ −3.68% | ▼ −1.69% | $0.8650 (−54.47%) |
Aug 14, 2026 10w ago | Press Release | $1.90 $1.83 | ▼ −3.68% | ▼ −1.69% | $0.8650 (−54.47%) |
Jul 30, 2026 12w ago | 8-K | $2.10 $1.80 | ▼ −14.29% | ▼ −18.25% | $0.8650 (−58.81%) |
Jul 7, 2026 16w ago | 8-K | $3.10 $2.02 | ▼ −34.84% | ▼ −36.17% | $0.8650 (−72.10%) |
May 14, 2026 23w ago | EFFECT | $3.96 $2.64 | ▲ +33.33% | ▲ +32.48% | $0.8650 (+78.16%) |
May 13, 2026 23w ago | EFFECT | $3.95 $2.71 | ▲ +31.39% | ▲ +30.78% | $0.8650 (+78.10%) |
May 8, 2026 24w ago | Press Release | $4.18 $2.89 | ▼ −30.86% | ▼ −30.88% | $0.8650 (−79.31%) |
Apr 23, 2026 26w ago | DEFA14A | $3.10 $3.59 | ▲ +15.81% | ▲ +11.78% | $0.8650 (−72.10%) |
Mar 31, 2026 30w ago | 8-K | $3.00 $3.06 | ▲ +2.00% | ▼ −7.72% | $0.8650 (−71.17%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers